Robert Schreiber, Elham Azizi receive 2024 Innovators in Science Award from NY Academy of Sciences

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Robert Schreiber

Elham Azizi

The New York Academy of Sciences has announced the winners of the 2024 Innovators in Science Award for their excellence in and commitment to innovative science that has significantly advanced the field of research in cancer immunology. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab), in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) followed by Sarclisa-Rd (the IMROZ regimen), significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly-diagnosed multiple myeloma not eligible for transplant. 

Login